Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: This systematic review and meta-analysis assess the efficacy and safety of rituximab (RTX) in treating idiopathic inflammatory myositis (IIM).
Methods: PubMed and Embase were systematically searched for trials and observational studies involving RTX use in IIM. Data were analyzed using a random-effects model to generate pooled estimates for overall response, complete remission, partial response, and adverse events, with subgroup analyses by myositis type and RTX dosage (PROSPERO registered number CRD42022353740). Risk of bias assessments were done using the Newcastle-Ottawa Scale for observational studies and risk of bias 1 tool for trials.
Results: Seventeen studies (1 randomized controlled trial and 16 observational studies), encompassing 362 patients, were included. The overall pooled response rate was 70% (95% confidence interval [CI]: 57%-82%; I2 = 74%, p < 0.001). Complete remission occurred in 13% (95% CI: 3%-25%; I2 = 79%, p < 0.001) and partial response in 48% (95% CI: 30%-67%; I2 = 87%, p < 0.001), both with significant heterogeneity. Subgroup analysis revealed high response rates across all myositis types: polymyositis 69%, dermatomyositis 67%, antisynthetase syndrome 70%, juvenile dermatomyositis 60%, and immune-mediated necrotizing myopathy 86%. Response rates were similar between RTX induction doses of 1 g IV on days 0 and 14 (68%) and 375 mg/m 2 weekly for 4 weeks (71%). Reported adverse events totaled 120, including infusion reactions (18.5%) and infections (12.4%).
Conclusions: RTX shows a favorable clinical response in IIM treatment, though response rates vary. There was a significant heterogeneity in treatment effect estimates that are based on a small number of patients. The incidence of infusion reactions and infections highlights the need for careful monitoring. Further controlled trials are essential to refine treatment protocols and evaluate long-term outcomes for RTX's role in IIM.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RHU.0000000000002151 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[One-year clinical results of the Multidisciplinary Consultation at the Emphysema Clinic of CHU Liege].
Rev Med Liege
September 2025
Service de Pneumologie, CHU Liège, Belgique.
Severe emphysema impairs lung function and quality of life in patients with Chronic Obstructive Pulmonary Disease (COPD). Despite optimized medical treatment and rehabilitation, some patients require lung volume reduction interventions (endoscopic or surgical). This study evaluates one-year outcomes of patients managed at the Emphysema Clinic of CHU Liège.
View Article and Find Full Text PDFDissecting the Causal Association Between Bulimia Nervosa and Structural Brain Abnormalities: A Two-Sample Bidirectional Mendelian Randomization Study.
Brain Behav
September 2025
The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
Background: Diverse correlations between structural brain abnormalities and the clinical feature of bulimia nervosa (BN) have been identified in previous observational studies.
Objective: To explore the bidirectional causality between BN and brain structural magnetic resonance imaging (MRI) phenotypes.
Methods: Genome-wide association studies (GWAS) of 2441 participants identified genetic variants associated with disordered eating and predicted BN, whereas UK Biobank 3D-T1 MRI data were used to analyze brain structural phenotypes.
Healthcare professionals' experiences in using a patient-reported outcome tool (PRO-Pall) to identify symptoms and problems in palliative care: A mixed-methods study.
Palliat Support Care
September 2025
REHPA, The Danish Knowledge Centre for Rehabilitation and Palliative Care, Odense University Hospital, Nyborg, Denmark.
Objectives: This study aimed to investigate healthcare professionals' experiences with using the PRO Palliative Care questionnaire (PRO-Pall) to identify palliative care symptoms and problems in non-specialized palliative care settings among patients with heart, lung, and kidney disease, and cancer. The study also investigated the PRO-Pall's potential to ensure further initiatives and care.
Methods: A national, multicenter, observational study employing a mixed-methods approach.
Real-World Evaluation of Botulinum Toxin A in Focal Peripheral Neuropathic Pain: Longitudinal Outcomes.
Eur J Neurol
September 2025
Pain Treatment and Evaluation Center, CHU Timone, Assistance Publique des Hôpitaux de Marseille, Marseille, France.
Background: Neuropathic pain (NP) is frequently resistant to conventional treatments. Botulinum toxin type A (BT-A) is a recommended option for focal peripheral NP, but the dynamics of its effect in real-life conditions remain poorly characterized.
Objective: To assess BT-A efficacy in a real-world study of patients with focal peripheral NP, over a 1-year follow-up period.
Dupilumab monotherapy in super-elderly patients with bullous pemphigoid: a retrospective study on long-term efficacy and safety in mild to moderate cases.
J Dermatolog Treat
December 2025
Department of Dermatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Background: Bullous pemphigoid (BP) is a common autoimmune subepidermal bullous disease. Dupilumab, an IL-4/IL-13 inhibitor, represents a novel therapeutic approach for BP, but real-world long-term data in super-elderly patients are limited.
Methods: This retrospective, single-center observational study included super-elderly BP patients (≥80 years) receiving dupilumab monotherapy from September 2022 to September 2024.